Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
Fox
H C
HC
Parrott
A C
AC
D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D006213:Hallucinogens / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis*; D006801:Humans; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis*; D009474:Neurons / Q000187:drug effects*; D011208:Powders; D019966:Substance-Related Disorders / Q000150:complications; D013607:Tablets
D006213:Hallucinogens; D011208:Powders; D013607:Tablets; D018817:N-Methyl-3,4-methylenedioxyamphetamine